GlassScriptPhysician profile
Maureen Kozlow
NPI 1659040020
$5,510.67
in general payments reported to CMS, 2019-2025
30 companies · $940 in 2025
The $940 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $1,246 · 2023: $1,436 · 2024: $1,236 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $796.56 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $571.86 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $547.89 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.32 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $353.77 | 2022-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $326.34 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Novartis Pharmaceuticals Corporation | $296.60 | 2022-2025 | |
| Silk Road Medical, INC. | $263.87 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $236.15 | 2024-2025 | Watchman Flx |
| Chiesi USA, INC. | $206.04 | 2021-2024 | Kengreal, Cleviprex |
| Novo Nordisk INC | $166.21 | 2023-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.93 | 2021-2025 | Lifevest |
| Genentech USA, INC. | $149.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2023 | Gattex |
| Pfizer INC. | $116.58 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $80.77 | 2023 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $76.62 | 2022 | |
| Scpharmaceuticals INC. | $68.20 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $65.11 | 2022-2025 | Farxiga |
| Tactile Systems Technology INC | $62.04 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Abbott Laboratories | $59.77 | 2022-2025 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $53.44 | 2023-2025 | |
| W. L. Gore & Associates, INC. | $36.76 | 2022 | |
| Heartflow, INC. | $33.99 | 2024 | |
| Lilly USA, LLC | $31.67 | 2025 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $28.30 | 2024 | |
| Elutia, INC. | $21.89 | 2022 | |
| Glaxosmithkline, LLC. | $20.83 | 2025 | Shingrix |
| Angiodynamics, INC. | $14.54 | 2022 | |
| Medicomp INC | $12.72 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Kozlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.